


Assessing depression's impact on neurocognitive performance in the NAMACO study



Galia Santos¹, Isabella Locatelli¹, Mélanie Métral¹, Alexandre Berney¹, Thanh Doco Lecompte², Alexandra Calmy², Helen Kovari³, Philip Tarr⁴, Patrick Schmid⁵, Ursi Kunze⁴, Isaure Nadin², Klemens Gutbrod⁶, Peter Brugger³, Katharine Darling¹, Renaud Du Pasquier¹, Matthias Cavassini¹ and the NAMACO study group

¹Lausanne University Hospital, ²Geneva University Hospitals, ³University Hospital Baselland, University of Basel, ⁵St. Gallen Canton Hospital, ⁶University Hospital of Bern

BACKGROUND

- In the era of potent antiretroviral therapy with suppressed blood HIV replication, HIV-associated neurocognitive disorders (HAND) remain a concern.
- This study aimed to analyze the link between depressive symptoms and neurocognitive impairment among well-treated HIV-positive patients.

METHODS

- Neurocognitive Assessment in the Metabolic and Ageing COhort (NAMACO) of the Swiss HIV Cohort Study (SHCS) is an ongoing prospective observational cohort study.
- Recruitment of 981 HIV-infected SHCS participants aged ≥ 45 years old from eight Swiss hospital centres between January 2013 and November 2016.

Tab. 2 Neurocognitive impairment, Centre for Epidemiologic Studies Depression (CES-D) score and drug use history among NAMACO study participants ¹ Answer "Yes definitely" to at least one of three screening questions.


Neurocognitive impairment (NCI) (N = 888) n (%)			
Normal neurocognitive examination	574 (64.6)		
Asymptomatic neurocognitive impairment	279 (31.4)		
Mild neurocognitive disorder	19 (2.1)		
Dementia	16 (1.8)		
Cognitive complaints ¹ (N = 897) n (%)	213 (23.8)		
CES-D score, (N = 895) median (IQR)	9 (4 – 16)		
< 16	643 (71.8)		
≥ 16, < 27	167 (18.7)		
≥ 27	85 (9.5)		
Antidepressant, (N = 902) n (%)	84 (9.3)		
Actual / past IV drug use, (N = 898) n (%)	117 (13.0)		
Cocaine consumption, (N = 901) n (%)	16 (1.8)		
Cannabis consumption, (N = 901) n (%)	90 (10.0)		

- Comprehensive and standardized neurocognitive assessment by neuropsychologists.
- Neurocognitive impairment classification based on the revised American Academy of Neurology diagnostic criteria for HAND diagnosis (Antinori et al.) without taking depressive symptoms into account.
- Depressive symptoms were assessed using the Centre for Epidemiologic
 Studies Depression (CES-D) scale (0–60).
- CES-D \geq 16: depression; CES-D \geq 27: severe depression
- Using the Wilcoxon-Mann-Whitney test, cross-sectional associations between
 CES-D scale and several factors were analysed.
- Univariate and multivariate analyses were performed on baseline data using regression models controlling for demographics, HIV infection characteristics and comorbidities, after exclusion of individuals with known neurological conditions increasing the risk of cognitive impairment.
- Depressive symptoms according to the CES-D scale were studied as potential predictors of the presence of neurocognitive impairment.

Fig. 1 Flowchart of patients analysed

Eligible population HIV positive patients ≥ 45 years old SHCS participants


8 Swiss Hospital Centres Jan 2013 to Nov 2016 N = 7067 Fig. 3 Several factors statistically significantly associated with the CES-D scale (Wilcoxon-Mann-Whitney test)



Upper red line: CES-D scale 27 (severe depression) - lower red line CES-D scale 16 (depression)

Tab. 3 CES-D scale and neurocognitive impairment

Adjustment variables: age, age², sex, ethnicity, education [years], time since cART initiation, time since cART initiation², HIV transmission risk group, nadir CD4 cell count (< 200, \geq 200 cells/µl), haemoglobin (categorical variable, according to



RESULTS

Tab. 1 Patient demographics, HIV infection characteristics ¹ Transfusion, perinatal transmission, uncertain cause.

	N = 902		
Age, [years] median (IQR)	53 (49 – 59)		
Sex , male, n (%)	726 (80.5)		
Ethnicity, n (%)			
Caucasian	839 (93.0)		
Other (African, Hispanic, Asian)	63 (7.0)		
Education, [years] median (IQR)	13 (12 – 14)		
HIV transmission risk group n (%)			
Homosexual contacts	491 (54.4)		
Heterosexual contacts	281 (31.2)		
IV drug use	65 (7.2)		
Other ¹	65 (7.2)		
Current CD4 cell count [cell/µl], median (IQR)	633 (466 – 820)		
Nadir CD4 cell count [cell/µl], median (IQR)	180 (75 – 272)		
Current plasma HIV-RNA [copies/ml] (N = 877), n (%)			
< 50	866 (96.1)		

sex: < lower limit of reference range, within reference range, > upper limit of reference range), platelet count, diabetes, arterial hypertension, antecedent of cardiovascular events, cannabis consumption, cocaine consumption, past and/or actual IV drug use, efavirenz prescription, positive Hepatitis C serology (exposure), positive Hepatitis B serology (exposure), positive syphilis serology (exposure).

CES-D scale	Crude effect			Adjusted effect		
Continuous	OR	95% CI	Ρ	OR	95% CI	Ρ
Ν		885			857	
Total	1.05	1.04 - 1.06	< 0.001	1.05	1.04 - 1.07	< 0.001
Ν		635			613	
< 16	1.08	1.04 - 1.12	< 0.001	1.08	1.03 - 1.13	0.002
Ν		250			244	
≥ 16	1.06	1.03 - 1.10	< 0.001	1.07	1.02 - 1.12	0.002
Dichotomized	OR	95% CI	Р	OR	95% CI	Р
Ν		885			857	
≥16	2.10	1.55 – 2.83	< 0.001	2.28	1.60 - 3.26	< 0.001
≥ 27	2.65	1.68 - 4.17	< 0.001	2.85	1.68 – 4.83	< 0.001

Fig. 4 CES-D scale and neurocognitive impairment, frequency distribution and ROC curve CES-D scale categories:





Fig. 2 Depression and neurocognitive impairment



CONCLUSION

- Depression is an important potential confounding factor when assessing neurocognitive performance in HIV-infected individuals, even with moderate depressive symptoms.
- The CES-D scale is a poor predictor of neurocognitive impairment.
- CES-D scale: the relationship between depressive symptoms and neurocognitive impairment is not characterized by a threshold; a cutoff at 16 predicts the presence of NCI with a sensitivity of 38.3% and a specificity of 77.2%.
- Better addressing depressive symptoms might potentially improve the neurocognitive outcome of HIV-infected patients.

The NAMACO study Group: Director: Matthias Cavassini Co-director: Renaud Du Pasquier Neuropsychologists Mélanie Métral, Samanta Simioni, Peter Brugger, Klemens Gutbrod, Andreas U. Monsch, Ursula Kunze, Isaure Nadin, Severin Früh, Marc Schwind, Riccardo Pignatti, Stefanie Clarke Neurologists: Frédéric Assal, Tobias Derfuss, Sebastian von Arx, Günter Eisele, Leonardo Sacco, Manuel Bertschi, Thomas Hundsberger, Renaud Du Pasquier Infectious Diseases specialists: Alexandra Calmy, Thanh Doco Lecompte, Christoph Hauser, Alexia Cusini, Rainer Weber, Helen Kovari, Barbara Hasse, Philip Tarr, Marcel Stoeckle, Christoph Fux, Enos Bernasconi, Caroline Di Benedetto, Alessandra Bruno, Patrick Schmid, Katharine Darling, Matthias Cavassini SHCS Data Centre: Alexandra Scherrer Data Management unit: Yannick Vallet, Deolinda Alves Statistician: Isabella Locatelli PharmD: Laurent Decosterd Neuro-Imaging specialists: Cristina Granziera, Gunnar Krueger, Reto Meuli, Maria Vargas.

